524606 — Beryl Drugs Balance Sheet
0.000.00%
- IN₹115.38m
- IN₹146.69m
- IN₹211.46m
- 52
- 34
- 37
- 33
Annual balance sheet for Beryl Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 6.58 | 12.2 | 15.6 | 6.61 | 9.43 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 46.5 | 45.8 | 69.2 | 75.8 | 54.6 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 102 | 106 | 103 | 102 | 90.4 |
| Net Property, Plant And Equipment | 73.2 | 58.6 | 58.1 | 59.6 | 60 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 186 | 178 | 175 | 175 | 160 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 82.1 | 84.9 | 63.3 | 57.6 | 43 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 107 | 105 | 94.5 | 85.6 | 64.6 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 79.3 | 72.9 | 80.7 | 89.2 | 95 |
| Total Liabilities & Shareholders' Equity | 186 | 178 | 175 | 175 | 160 |
| Total Common Shares Outstanding |